Cambridge Healthtech Institute’s 4th Annual
Next-Generation Immunotherapies
May 15-16, 2025
The immunotherapy field has made extraordinary progress in recent times, but challenges still remain around targeting, delivery, efficacy, and safety. Which (re)emerging technologies and modalities will shape the future of immunotherapies over the next 5-10 years to help overcome the limitations of current therapies? Cambridge Healthtech Institute’s 4th Annual Next-Generation Immunotherapies conference explores the next wave of immune reprogramming platforms, including in vivo engineering and delivery to immune cells, cancer vaccines, emerging cell therapies, mRNA and RNA therapies, nanomedicines, and more.
Coverage will include, but is not limited to:
- In vivo engineering of immune cells—lenti, AAV, mRNA, RNA approaches
- mRNA-based therapies for cancer immunotherapy
- Cancer vaccines
- Emerging cell therapies
- TCR-T Therapies
- Oncolytic viruses
- Oligonucleotides, RNAi conjugates
- Novel delivery methods
- Nanomedicine
- Microbiome, viral, and bacterial-based immunotherapies
The deadline for priority consideration is October 11, 2024.
AAll proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: